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OBJECTIVES: To examine the disability and resource
utilisation associated with osteo- and rheumatoid arthri-
tis in five European countries.
METHODS: A large international database was exam-
ined to evaluate the disability and resource use in patients
with rheumatoid and osteo-arthritis. The database in-
cluded the Health Assessment Questionnaire (HAQ) Dis-
ability Index, questions on satisfaction and questions on
resource utilisation and lost work time.
RESULTS: The Arthritis Disease Specific Programme,
held by Adelphi Ltd, was used as the database for this
study. It contains 4580 patient records, 4203 of which
have self-reported HAQ data. HAQ data are reported for
France (n  609), Germany (n  1079), Italy (n  796),
Spain (n  1229), and the UK (n  490). Patients with
rheumatoid arthritis (n  2022) consistently demonstrate
more disability than those with osteoarthritis (n  1836)
(HAQ DI: 1.03 vs 1.01, respectively). Patients in the UK
had the most RA and OA disability (HAQ DI 1.60 and
1.20, respectively). Within disease diagnoses, females had
greater disability (1.08 vs 0.90 RA; 1.05 vs 0.95 OA). Pa-
tients with RA tend to have more GP and specialist visits
over six months compared to those with OA (3.30 and
1.79 vs 3.26 and 1.41), although OA patients tend to
have more ED visits (0.14 vs 0.07). Self-reported days off
work over six months were also greater for RA patients
(25.44 vs 20.24). The greatest work absences were seen
in the UK (RA: 45.00; OA: 41.10) and the least days off
work were seen in Italy (RA: 7.09; OA: 4.24).
CONCLUSIONS: OA and RA have large impacts on dis-
ability and resource utilization in the European countries
we examined. Although debilitating, the extent to which
resources are consumed and work lost varies greatly from
country to country. From this cross-sectional interna-
tional database, RA patients have greater disability com-
pared to OA. This is reflected by higher disability, greater
resource utilisation, and more days off work.
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OBJECTIVE: To examine the reliability and validity of a
new French questionnaire assessing patient satisfaction
with their osteoarthritis (OA) treatment.
METHODS: Item generation: Semi-structured interviews
were performed among 20 osteoarthritis (OA) patients and
10 clinicians. Interviews were recorded, transcribed and an-
alyzed. Content validity and cognitive debriefing of the first
version of the Arthritis Treatment Satisfaction (ARTS) ques-
tionnaire was evaluated by 10 OA patients. Validation
study: Principal component analysis, multi-trait analysis, in-
ternal consistency (Cronbach’s alpha) and known-group va-
lidity were performed on a cross-sectional sample of 797
OA patients. Test-retest was assessed on 133 clinically sta-
ble OA patients. Test-retest reliability was estimated with
the Intraclass Correlation Coefficient (ICC).
RESULTS: Patients were on average 67.5 years old (SD 
10.4), 64.5% were women, 26% had OA of the hip,
58% had OA of the knee, and all patients had suffered
from OA for an average of 7 years (SD  6.4). The re-
sulting ARTS questionnaire comprised 18 items consist-
ing of a clear four dimensional structure measuring
advantages of treatment, treatment convenience, appre-
hensions about treatment and satisfaction with medical
care. Scores were calculated using the mean of items in
each dimension. Cronbach’s alpha ranged from 0.63 for
treatment convenience to 0.86 for advantages of treat-
ment. ICC ranged from 0.61 for advantages of treatment
to 0.75 for treatment convenience. ARTS significantly
differentiated patients according to the presence of side
effects, regular practice of physical activity, perceived
pain and indices of severity.
CONCLUSION: Results provide evidence for the good psy-
chometric properties of this first treatment-satisfaction ques-
tionnaire specific to osteoarthritis. The responsiveness of the
ARTS questionnaire over time is still to be documented.
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OBJECTIVE: To evaluate the economic efficiency of
management guidelines for corticosteroid-induced os-
teoporosis and establish whether it is more economically
efficient to modify the guidelines when targeting respira-
tory patients.
METHODS: Data were collected from GP medical
records related to osteoporosis risk factors and cortico-
steroid use in the previous year. Sample data were used
for economic modelling based on population data and
costs from literature. Three strategies were evaluated: the
existing guidelines; modified guidelines; treatment with-
out reference to guidelines. Main outcome measures were
net discounted cost per fracture averted and net dis-
counted cost per quality adjusted life year (QALY) saved.
RESULTS: A cohort of 110 (71 women) adult patients
prescribed oral and/or inhaled corticosteroids was identi-
fied. Following existing guidelines averted 0.5 fractures
and saved 0.1 QALYs at a net total cost of £5,943. The
resultant cost per fracture averted is £12,506 and cost per
QALY saved is £40,356. When modified, to include in-
termittent oral and inhaled corticosteroid use as risk fac-
tors, the net total costs increased to £30,190, with 3.6
fractures averted and 1.1 QALYs saved resulting in a cost
per fracture averted of £8,419 and cost per QALY saved
of £27,854, representing greater economic efficiency. Fur-
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ther reductions in costs with no detriment to benefits
were seen when modified risk criteria were in the guide-
lines were not followed and bone mass density measure-
ments and diagnostic testing were excluded. Sensitivity
analysis of the results identified sex as a major influence
on cost effectiveness. When men were excluded, favour-
able reductions were seen in the cost per fracture averted
and cost per QALY saved.
CONCLUSION: When managing corticosteroid-induced
osteoporosis in respiratory patients, this study showed
that it was more cost-effective to use modified guidelines
than existing guidelines. The modifications proposed are
to include risk assessment criteria for sex, and use of in-
termittent oral and inhaled corticosteroids.
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The prevalence of osteoporosis is expected to increase
from 10.1 million in 1996 to 14.7 million in 2015 (NOF,
1997). Medical cost was estimated to be $13.8 billion in
1995, but growth has not been predicted.
OBJECTIVE: To estimate the direct medical cost of os-
teoporotic fractures in the US in 2000-2025.
METHODS: Cost of osteoporosis for women aged 50 to 99
was predicted using a Markov model, which tracked cohort
movements across fracture-outcome states. We ran 50 con-
secutive cohorts from age 50 to 99, each with a 25-year fol-
low-up. Average cost at each patient age was adjusted by os-
teoporosis attribution rates. Then the population of women
aged 50 to 99 was multiplied by the age-specific average
cost to determine total cost by age within each year (2000–
2025). Because fracture incidence rates were unavailable for
men and for “other” fracture types in women, these costs
were estimated by multiplying base year costs by the respec-
tive population increases over time. Unit costs for hospital
inpatient care were estimated by fracture type from the Na-
tionwide Inpatient Sample, applying high-cost outlier edits
and a 20% payer discount. For non-hip fractures, we multi-
plied mean hospital charges by 0.10 to 0.159 to reflect the
low proportion of fractures resulting in hospitalization. Pri-
mary and long-term care costs were obtained from pub-
lished national estimates.
RESULTS: In 2000, we estimate that osteoporosis caused
1.2 million fractures in the U.S. at a direct medical cost of
$16.2 billion. Three-fourths of fractures occurred in indi-
viduals age 75 and older, and over one third (35%) oc-
curred in nursing facilities. Annual cost is projected to
grow by 58% to $25.6 billion in 2025.
CONCLUSION: Without change in medical practice,
this preventable disease will impose a substantial burden
on the US health-care system as the population ages.
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OBJECTIVE: After community pharmacists in five states
attended a Women’s Health Pharmaceutical Care certifi-
cation program, we evaluated pharmacists’ interventions
provided to osteoporosis patients.
METHODS: Pharmacists participated in a six-topic
Women’s Health Educational program including self-
study modules and live continuing education. Pharma-
cists faxed intervention-report forms to researchers re-
porting patient’s problems, pharmacist interventions, and
intervention outcomes for patients. This report focuses
on interventions for osteoporosis.
RESULTS: Female patients (n  140) identified with
medication issues related to osteoporosis were provided
pharmaceutical care. The mean age of these patients was
51.29, SD 9.85. The most common drug-related prob-
lems were untreated indications or the need for an addi-
tional drug (42.9%), and side effects from a medication
(17.9%). The highest adherence problem was that pa-
tients discontinued their medications (51.4%). In 90% of
the cases, the pharmacists provided interventions directly
to the patients by giving patient education about medica-
tions, disease management, and alternative therapy.
Pharmacists suggested the patients talk with their physi-
cian about prescription products in 37.1% of the cases.
In another 17.9% of cases they contacted physicians for
recommended medications or to schedule an appoint-
ment for the patient. About 25% of the patients were
scheduled to see their physician or received a new drug
from the physicians. Pharmacists recommended over-the-
counter (OTC) drugs or vitamins and minerals to 35.7%
patients. In 32.9% of the cases, the patient added OTC
drugs or vitamins and minerals. Pharmacists spent an av-
erage of 14 minutes with each patient to identify and pro-
vide interventions for specific problems. In 85.1% of the
interventions the pharmacist felt confident to provide
pharmaceutical care for the osteoporosis patients.
CONCLUSIONS: Community pharmacists are in a
prime location to identify patients at risk for medication
problems related to osteoporosis. These data suggest that
when pharmacists identify problems with drug therapy,
positive outcomes occur.
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